Related Articles by Review for PMID: 30821231

Year	Number of Results
2001	1
2006	3
2007	6
2008	1
2009	1
2010	2
2011	5
2012	18
2013	14
2014	15
2015	13
2016	11
2017	16
2018	6
2019	4
2020	11
2021	17
2022	31
2023	32
2024	12

1

Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.

Tappenden P, Carroll C, Hamilton J, Kaltenthaler E, Wong R, Wadsley J, Moss L, Balasubramanian S. Tappenden P, et al. Health Technol Assess. 2019 Feb;23(8):1-144. doi: 10.3310/hta23080. Health Technol Assess. 2019. PMID: 30821231 Free PMC article.

2

Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation.

Edwards SJ, Wakefield V, Cain P, Karner C, Kew K, Bacelar M, Masento N, Salih F. Edwards SJ, et al. Health Technol Assess. 2018 Jan;22(6):1-278. doi: 10.3310/hta22060. Health Technol Assess. 2018. PMID: 29393024 Free PMC article. Review.

3

Vandetanib for the treatment of medullary thyroid carcinoma.

Cooper MR, Yi SY, Alghamdi W, Shaheen DJ, Steinberg M. Cooper MR, et al. Ann Pharmacother. 2014 Mar;48(3):387-94. doi: 10.1177/1060028013512791. Epub 2013 Nov 14. Ann Pharmacother. 2014. PMID: 24259657 Review.

4

Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer.

Hadoux J, Schlumberger M. Hadoux J, et al. Best Pract Res Clin Endocrinol Metab. 2017 Jun;31(3):335-347. doi: 10.1016/j.beem.2017.04.009. Epub 2017 Apr 28. Best Pract Res Clin Endocrinol Metab. 2017. PMID: 28911729 Review.

5

The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.

Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P, Ryan A. Hind D, et al. Health Technol Assess. 2008 May;12(15):iii-ix, xi-162. doi: 10.3310/hta12150. Health Technol Assess. 2008. PMID: 18462574 Free article. Review.

6

Cabozantinib: a review of its use in patients with medullary thyroid cancer.

Hoy SM. Hoy SM. Drugs. 2014 Aug;74(12):1435-44. doi: 10.1007/s40265-014-0265-x. Drugs. 2014. PMID: 25056653 Review.

7

Systemic treatment and management approaches for medullary thyroid cancer.

Ernani V, Kumar M, Chen AY, Owonikoko TK. Ernani V, et al. Cancer Treat Rev. 2016 Nov;50:89-98. doi: 10.1016/j.ctrv.2016.09.006. Epub 2016 Sep 10. Cancer Treat Rev. 2016. PMID: 27664392 Review.

8

The safety of vandetanib for the treatment of thyroid cancer.

Tsang VH, Robinson BG, Learoyd DL. Tsang VH, et al. Expert Opin Drug Saf. 2016 Aug;15(8):1107-13. doi: 10.1080/14740338.2016.1201060. Epub 2016 Jul 4. Expert Opin Drug Saf. 2016. PMID: 27301016 Review.

9

The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer.

Fallahi P, Ferrari SM, Baldini E, Biricotti M, Ulisse S, Materazzi G, Miccoli P, Antonelli A. Fallahi P, et al. Expert Rev Anticancer Ther. 2016 Nov;16(11):1109-1118. doi: 10.1080/14737140.2016.1238764. Epub 2016 Sep 30. Expert Rev Anticancer Ther. 2016. PMID: 27650489 Review.

10

Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.

Brown T, Pilkington G, Bagust A, Boland A, Oyee J, Tudur-Smith C, Blundell M, Lai M, Martin Saborido C, Greenhalgh J, Dundar Y, Dickson R. Brown T, et al. Health Technol Assess. 2013 Jul;17(31):1-278. doi: 10.3310/hta17310. Health Technol Assess. 2013. PMID: 23886301 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

196 results

Results by year